Terms: = Breast cancer AND CD52, CDW52, EDDM5
9 results:
1. Neoadjuvant chemotherapy-induced remodeling of human hormonal receptor-positive breast cancer revealed by single-cell RNA sequencing.
Jia F; Sun S; Li J; Wang W; Huang H; Hu X; Pan S; Chen W; Shen L; Yao Y; Zheng S; Chen H; Xia W; Yuan H; Zhou J; Yu X; Zhang T; Zhang B; Huang J; Ni C
Cancer Lett; 2024 Mar; 585():216656. PubMed ID: 38266804
[TBL] [Abstract] [Full Text] [Related]
2. cd52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D
Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic and immune implications of a novel 7-methylguanosine-related microRNA signature in breast invasive carcinoma: from exploration to validation.
Li AY; Xiao HN; Zhao ZY; Xiang C; Chen ZY; Wang PX; Xia Y; Yu B; Li H; Xiao T
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9105-9128. PubMed ID: 37171615
[TBL] [Abstract] [Full Text] [Related]
4. [CD40LG is a novel immune- and stroma-related prognostic biomarker in the tumor microenvironment of invasive breast cancer].
Guo L; Ma Y; Li T; Li J
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Sep; 42(9):1267-1278. PubMed ID: 36210698
[TBL] [Abstract] [Full Text] [Related]
5. Immunophenotype-associated gene signature in ductal breast tumors varies by receptor subtype, but the expression of individual signature genes remains consistent.
Behring M; Ye Y; Elkholy A; Bajpai P; Agarwal S; Kim HG; Ojesina AI; Wiener HW; Manne U; Shrestha S; Vazquez AI
Cancer Med; 2021 Aug; 10(16):5712-5720. PubMed ID: 34189853
[TBL] [Abstract] [Full Text] [Related]
6. CD2 Is a Novel Immune-Related Prognostic Biomarker of Invasive breast Carcinoma That Modulates the Tumor Microenvironment.
Chen Y; Meng Z; Zhang L; Liu F
Front Immunol; 2021; 12():664845. PubMed ID: 33968066
[TBL] [Abstract] [Full Text] [Related]
7. Autologous Natural Killer Cell-enrichment for Immune Cell Therapy: Preclinical Setting Phase, Shiraz Experience.
Rezaeifard S; Heike Y; Masuyama JI; Rezvani A; Vojdani R; Erfani N
Iran J Allergy Asthma Immunol; 2021 Apr; 20(2):233-243. PubMed ID: 33904681
[TBL] [Abstract] [Full Text] [Related]
8. [New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies].
Aguillón JC; Contreras J; Dotte A; Cruzat A; Catalán D; Salazar L; Molina MC; Guerrero J; López M; Soto L; Salazar-Onfray F; Cuchacovich M
Rev Med Chil; 2003 Dec; 131(12):1445-53. PubMed ID: 15022409
[TBL] [Abstract] [Full Text] [Related]
9. Monoclonal antibodies in human cancer.
Mellstedt H
Drugs Today (Barc); 2003; 39 Suppl C():1-16. PubMed ID: 14988743
[TBL] [Abstract] [Full Text] [Related]
